EDAP TMS S.A. — FY 2016 Form 20-F
Reporting period: Year ended December 31, 2016. This is an annual audited filing, not a standalone fourth-quarter report. Financial statements are prepared under U.S. GAAP and reported in euros.
Business context
EDAP develops and sells minimally invasive medical devices, principally HIFU systems for prostate cancer treatment and ESWL lithotripters for urinary stones. Its divisions are HIFU and Urological Devices and Services (UDS). The filing was submitted April 3, 2017.
Key financial metrics
Amounts below are in millions of euros unless otherwise stated.
| Metric | FY 2016 | FY 2015 | Change / context |
|---|---|---|---|
| Total revenue | 35.6 | 32.3 | Up 10.4% |
| Gross profit / margin | 16.4 / 46.1% | 13.8 / 42.8% | Margin improved 3.3 percentage points |
| Operating expenses | 16.0 | 13.3 | Up 20.5% |
| Operating income | 0.4 | 0.5 | Positive for second consecutive year |
| Net income (loss) | 3.8 | (1.7) | Turned profitable; substantially affected by warrant fair-value gains |
| Operating cash flow | 1.1 | 1.3 | Positive, slightly lower |
| Cash and equivalents at year-end | 22.0 | 13.6 | 2016 increase included financing proceeds |
| Total current assets / liabilities | 40.5 / 15.0 | 33.0 / 16.3 | Working capital was approximately 25.5 |
| Debt and capital leases | 2.8 | 4.2 | Short-term borrowings 1.6; long-term debt 0.6; capital leases 0.5 |
FY 2016 net financial income was €3.9 million, including a €3.8 million gain from changes in warrant fair value. This non-cash valuation item was a major reason net income exceeded operating income. Diluted earnings per share were €0.13; basic earnings per share were €0.14.
Material changes versus FY 2015
- HIFU revenue rose 63% to €13.8 million, with six Ablatherm and eight Focal One systems sold, versus two and five, respectively, in 2015. HIFU operating profit increased to approximately €1.0 million from €0.5 million.
- UDS revenue declined 8.3% to €21.8 million. Lithotripter sales fell to 36 units from 52; parts, service, leasing and procedure-related sales rose modestly. UDS operating profit decreased to €0.7 million from €1.6 million.
- R&D expense rose 43.8% to €3.9 million and sales and marketing expense increased to €8.9 million, contributing to higher operating expenses.
- Gross margin improved as HIFU sales grew, while operating income edged down because expense growth more than offset higher gross profit.
- Cash rose by €8.4 million. The company attributed the increase principally to the April 2016 financing and positive operating cash flow; investing activities used €0.4 million and financing activities generated €7.7 million.
Outlook, commentary and risks
- Management expects sales and marketing spending to increase significantly in 2017, particularly as the company expands in the United States. It expects European R&D spending to run at approximately 13% of revenue, supporting clinical studies, regulatory work and development of HIFU applications beyond prostate cancer.
- Management expects the mature ESWL market and UDS activity to remain broadly stable in the foreseeable future. Future performance depends on HIFU adoption, sales growth, expense control and Focal One’s U.S. regulatory process.
- Ablatherm received U.S. 510(k) clearance in 2015 for prostate tissue ablation. Focal One’s U.S. 510(k) application, submitted in April 2016, remained under FDA review at filing. The filing cautions that regulatory clearance does not assure reimbursement or broad market acceptance.
- HIFU procedure reimbursement remained limited by country. Japan stopped reimbursing lithotripter electrodes in 2016, adversely affecting related sales. Revenue and cash flow are also exposed to cyclical hospital purchasing, currency movements, competition and customer payment risk.
- Principal operating risks include dependence on HIFU commercialization, clinical and regulatory uncertainty, a single manufacturing facility in France, reliance on some single-source suppliers, product liability, intellectual-property disputes and warrant-related dilution. The filing says up to approximately 5.97 million shares could be issuable under outstanding warrants and options, about 20.6% of issued share capital based on the stated calculation.
- No dividends were paid for 2016, and the company did not anticipate paying one. The prior securities class action was dismissed in 2015 with no appeal. In March 2017, France’s Conseil d’État rejected the company’s appeal concerning recovery of €772,000 in state aid previously repaid.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor reported effective controls as of year-end.
Investor verification priorities
- Reconcile reported net income to operating performance, especially the €3.8 million warrant fair-value gain and the associated warrant liability.
- Review financing terms, warrant exercise and dilution potential, and the fully diluted share count.
- Track Focal One’s FDA review, U.S. commercialization progress, procedure reimbursement and HIFU adoption.
- Assess UDS sales trends and the continuing impact of Japan’s electrode reimbursement change.
- Verify liquidity and debt maturities alongside working-capital needs, planned U.S. spending and the company’s reliance on operating cash generation.